IMPACT OF ARTIFICIAL INTELLIGENCE ON THE DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY WITH THE IMPLICATIONS OF IPR
Abstract
This paper explores the transformative impact of Artificial Intelligence (AI) in the pharmaceutical industry and its implications for Intellectual Property Rights (IPR). It highlights the key contributions of AI across drug discovery, clinical trials, and personalized medicine, revolutionizing these critical aspects of pharmaceutical research. AI accelerates drug discovery, streamlines clinical trials, and personalizes treatments, offering the potential for faster, more cost-effective and patient-centric healthcare solutions. However, alongside these advancements, the paper underscores the multifaceted challenges posed by AI in the realm of IPR. It delves into the intricacies of patentability for AI-generated inventions and addresses issues of data ownership, privacy, and ethical considerations. The paper emphasizes the urgent need for adaptations in IPR laws and regulations to align with the evolving landscape of AI-driven innovation in pharmaceuticals, striking a balance between protecting intellectual property and fostering collaboration and ethical use of AI technologies for the betterment of healthcare worldwide.
Keyword : Artificial Intelligence (AI), Intellectual Property Rights (IPR), pharmaceutical industry, healthcare.
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
• G. Arora et al., "Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19," Pathogens 10, no. 8 (2021): 1048. • N. Ayati, P. Saiyarsarai & S. Nikfar, "Short and Long Term Impacts of COVID-19 on the Pharmaceutical Sector," DARU Journal of Pharmaceutical Sciences 28 (2020): 799-805. • J. Bajorath et al., "Artificial Intelligence in Drug Discovery: Into the Great Wide Open," Journal of Medicinal Chemistry 63, no. 16 (2020): 8651-8652. • M. Beil et al., "Ethical Considerations about Artificial Intelligence for Prognostication in Intensive Care," Intensive Care Medicine Experimental 7, no. 1 (2019): 1-13. • Bender & I. Cortés-Ciriano, "Artificial Intelligence in Drug Discovery: What is Realistic, What Are Illusions? Part 1: Ways to Make an Impact, and Why We Are Not There Yet," Drug Discovery Today 26, no. 2 (2021): 511-524. • S.K. Bhattamisra et al., "Artificial Intelligence in Pharmaceutical and Healthcare Research," Big Data and Cognitive Computing 7, no. 1 (2023): 10. • G. Briganti & O. Le Moine, "Artificial Intelligence in Medicine: Today and Tomorrow," Frontiers in Medicine 7 (2020): 27. • J. Cai, H. Zhao & P.C. Coyte, "The Effect of Intellectual Property Rights Protection on the International Competitiveness of the Pharmaceutical Manufacturing Industry in China," Engineering Economics 29, no. 1 (2018): 62-71. • L.A.M. Chowdhury, T. Rana & M.I. Azim, "Intellectual Capital Efficiency and Organisational Performance: In the Context of the Pharmaceutical Industry in Bangladesh," Journal of Intellectual Capital 20, no. 6 (2019): 784-806. • J. Guan, "Artificial Intelligence in Healthcare and Medicine: Promises, Ethical Challenges and Governance," Chinese Medical Sciences Journal 34, no. 2 (2019): 76-83. • Hasselgren & T.I. Oprea, "Artificial Intelligence for Drug Discovery: Are We There Yet?," Annual Review of Pharmacology and Toxicology 64 (2023). • Juarez-Lopez & A. Schcolnik-Cabrera, "Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments," Archives of Medical Research 52, no. 3 (2021): 243-251. • Kulkov, "The Role of Artificial Intelligence in Business Transformation: A Case of Pharmaceutical Companies," Technology in Society 66 (2021): 101629. • K.K. Mak & M.R. Pichika, "Artificial Intelligence in Drug Development: Present Status and Future Prospects," Drug Discovery Today 24, no. 3 (2019): 773-780. • R. Manne & S.C. Kantheti, "Application of Artificial Intelligence in Healthcare: Chances and Challenges," Current Journal of Applied Science and Technology 40, no. 6 (2021): 78-89. • K. Martinez-Mayorga et al., "The Impact of Chemoinformatics on Drug Discovery in the Pharmaceutical Industry," Expert Opinion on Drug Discovery 15, no. 3 (2020): 293-306. • M.A.I. Mozumder et al., "Metaverse for Digital Anti-Aging Healthcare: An Overview of Potential Use Cases Based on Artificial Intelligence, Blockchain, IoT Technologies, Its Challenges, and Future Directions," Applied Sciences 13, no. 8 (2023): 5127. • N. Nagarajan et al., "Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery," BioMed Research International (2019). • N. Naik et al., "Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility?," Frontiers in Surgery 9 (2022): 266. • R.R. Narayanan, N. Durga & S. Nagalakshmi, "Impact of Artificial Intelligence (AI) on Drug Discovery and Product Development," Indian J. Pharm. Educ. Res 56 (2022): S387-S397. • V. Pareek et al., "Need for Artificial Intelligence in Pharmaceutical Industry and Its Limitations," Journal of the Indian Academy of Geriatrics 18, no. 4 (2022): 217-220. • Paul et al., "Artificial Intelligence in Drug Discovery and Development," Drug Discovery Today 26, no. 1 (2021): 80. • Rosemann & X. Zhang, "Exploring the Social, Ethical, Legal, and Responsibility Dimensions of Artificial Intelligence for Health," Intelligent Medicine 2, no. 2 (2022): 103-109. • M.Y. Shaheen, "Applications of Artificial Intelligence (AI) in Healthcare: A Review," ScienceOpen Preprints (2021). • R. Snyder, "Literature Review as a Research Methodology: An Overview and Guidelines," Journal of Business Research 104 (2019): 333-339. • Thakur et al., "Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies," Current Pharmaceutical Design 26, no. 29 (2020): 3569-3578. • L.K. Vora et al., "Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design," Pharmaceutics 15, no. 7 (2023): 1916. • X. Yang et al., "Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery.